Over the last decade, treatment options for lung cancer patients have evolved drastically. Even in just the last few months, promising research has led to new, approved therapies, and researchers anticipate more advances are on the way. “Drugs are emerging at a rapid pace now,” says Geoffrey Oxnard, MD, of Dana-Farber’s Lowe Center for Thoracic … Continued
This post is adapted from an article that originally appeared on the Huffington Post. Over the past decade, researchers have made great strides in targeted therapy and immunotherapy for lung cancer, offering hope to patients with the deadliest form of cancer in the United States. In addition to seeking innovative medical care, patients can also … Continued
As the wife of a New England sportscaster, and the sister and mother of athletes, Lisa Eid understands sports metaphors. So when the 48-year-old non-smoker learned that she had stage IV lung cancer last year, she knew what her husband, Dave, meant when he said, “We need to find the Tom Brady of lung cancer … Continued
The year 2015 marked a milestone in the treatment of lung cancer, with two new immunotherapy drugs approved for patients with advanced disease, bringing a new approach to this hard-to-treat cancer. Several other immunotherapy agents are also moving forward in clinical trials. In the past few years, scientists have found ways to disable the molecular … Continued
The FDA announced today it has approved a new pill to treat certain patients with advanced non-small cell lung cancer (NSCLC). The oral medication, Tagrisso (osimetinib), has been approved for NSCLC patients whose tumors have a specific epidermal growth factor receptor (EGFR) mutation (T790M) and whose disease has worsened after treatment with other EGFR-blocking therapy. … Continued
This post originally appeared on the Brigham and Women’s Health Hub Blog. Lung cancer is the leading cause of cancer deaths among men and women in the United States. For women, it accounts for more deaths than breast, ovarian, and uterine cancer combined. Consequently, medical researchers have been working hard to increase our understanding of … Continued
The Food and Drug Administration’s approval of the drug Iressa® for a form of metastatic lung cancer represents a return to prominence for the compound that launched the era of targeted therapy in lung cancer – even if that wasn’t clear at the time of its original clinical trial in patients. The FDA approved Iressa (gefitinib) … Continued
Even before President Barack Obama declared it a national initiative, precision medicine has helped bring more effective treatment to patients with many types of cancer. One disease that has benefited from these treatments is lung cancer, where targeted therapies have significantly improved outcomes for patients. “When we find we have drugs targeted for a specific … Continued
Any cancer diagnosis and treatment can take a physical and emotional toll on patient. For many lung cancer patients, post-operative pain and muscle tension, as well as breathing and sleeping issues, are common side effects. To help ease some of these symptoms, patients can seek out integrative therapies, which can be used in conjunction with standard … Continued
Lung cancer remains the most deadly form of cancer in the United States, with nearly 160,000 deaths annually and more than 224,000 new cases expected in 2014. While many lung cancer diagnoses are linked to smoking, nonsmokers can develop the disease as well and should be aware of their risks. Anyone can get lung cancer. … Continued
Lung cancer, which causes more deaths worldwide than any other malignancy, is revealing its vulnerabilities under a sustained assault from science. Many of the most recent advances against the disease have a long pedigree at Dana-Farber. It was 10 years ago, in fact, that Dana-Farber scientists and elsewhere showed non-small cell lung cancers that carry … Continued
Ten years ago researchers at Dana-Farber and in Japan published a study showing that lung cancer patients whose tumors had a malfunctioning version of a protein called Epidermal Growth Factor Receptor (EGFR) responded dramatically to a drug that specifically targets the EGFR protein. The findings launched the era of precision medicine for lung cancer, transforming … Continued
Experts with the U.S. Preventive Services Task Force (USPSTF) have recommended that current smokers and former-smokers who recently quit should undergo an annual low-dose CT scan to screen for lung cancer.
Despite the research, the promising new drugs, the many ongoing clinical trials, lung cancer remains a disease that affects too many people, too often. For patients and family members, the disease carries an added burden: a stigma that lung cancer and smoking go hand in hand, and that lung cancer patients brought this on themselves. … Continued
Medically reviewed by Pasi A. Jänne, MD, PhD Lung cancer develops in the tissue of the lung, usually in the cells that line the air passages. Here are some common questions about the disease, answered by Pasi A. Jänne, MD, PhD, Director of Dana-Farber’s Lowe Center for Thoracic Oncology. What are the types of lung cancer? There are … Continued
Lung cancer can be a frightening diagnosis. However, new treatment approaches and promising research trends have made the outlook for patients a little more optimistic, says David Jackman, MD, an oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute.
While other kinds of cancer may receive more public attention, lung cancer remains the leading cause of cancer deaths. There are two main types of lung cancer: small cell carcinoma and non-small cell carcinoma, both of which mainly affect people over 45 years old. We spoke with Bruce E. Johnson, MD about causes and treatment options.